sglt2 semaglutide Effects of with and without concomitant inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial SGLT2 Inhibitors vs. GLP-1 Agonists

Semaglutide GLP-1 injections contain a peptide very similar to glucagon, a hormone that we naturally produce to help lower our blood sugar after eating by stimulating insulin release and blocking the production of sugar

[DOI] [PubMed] [Google Scholar] 100.Zheng W, Pan H, Wei L, Gao F, Lin X

References 1.Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C et al

Results May Vary: Individual results from GLP-1 treatment vary based on starting weight, health status, adherence, clinician guidance, lifestyle factors, and duration of treatment

Prolonged cAMP signaling and homologous desensitization Intuitively, reduced loss of surface GLP-1R with exendin-phe1 should permit greater access to extracellular ligand during continuous exposure, with fast recycling ensuring that the receptors are maintained in a sensitized state